- Global Pharma News & Resources

Gossamer Bio Announces Appointment of Jakob Dupont, M.D. as Chief Medical Officer

Gossamer Bio, Inc., a privately held, clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has appointed Jakob Dupont, M.D. as Chief Medical Officer. Dr. Dupont has nearly 20 years of academic, biotechnology and pharmaceutical drug development experience, from early clinical phase through post-commercialization.

“Gossamer has grown rapidly during the past year and has a meaningful pipeline of exciting clinical and preclinical drug candidates,” said Sheila Gujrathi, M.D., Gossamer Bio’s Co-Founder and Chief Executive Officer. “Jakob’s extensive clinical development and regulatory expertise comes at a critical time for the company as we accelerate our development and look ahead to multiple significant clinical milestones. Jakob’s deep experience across the spectrum of therapeutic clinical development is an ideal fit, and we are thrilled to welcome him to the Gossamer team.”

“Gossamer’s program pipeline addresses a number of significant disease areas that continue to be underserved by currently available therapies,” said Dr. Dupont. “I am excited to be joining the team to advance these important potential new treatments in an environment that combines a rare blend of the nimbleness of an early-stage biotech company with the resources, expertise and rigor of a much more mature company.”

Dr. Dupont most recently served as Vice President and Global Head of Breast and Gynecologic Cancer Development and was a member of the Oncology Leadership Team for Genentech/Roche. He was responsible for global development of Herceptin®, Perjeta®, Kadcyla®, ipatasetib, taselisib, and Tecentriq®, among others, and co-led the Genentech/Roche Breast Cancer Disease Area Strategy Team. Prior to his recent role at Genentech/Roche, Dr. Dupont was Chief Medical Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc. where he oversaw clinical development and regulatory activities in oncology and other therapeutic areas. These activities included investigational new drug applications (INDs), clinical trials initiation, conduct and analysis. Dr. Dupont also participated in the execution of corporate initiatives, including OncoMed’s initial public offering and a partnership agreement with Celgene. Dr. Dupont began his career in the biotechnology industry with Genentech/Roche where he served as Global Medical Director of Avastin® and was Group Director and Medical Director overseeing the angiogenesis pipeline, playing a key role in the development and approval of Avastin in ovarian, cervical and breast cancers as well as IND filings of novel anti-angiogenic agents. Prior to first joining Genentech/Roche in 2006, Dr. Dupont was a faculty member and laboratory researcher at Memorial Sloan-Kettering (MSK) Cancer Center and oversaw a solid tumor and GYN oncology clinic and a tumor immunology laboratory. He also served as adjunct clinical faculty in medical oncology at Stanford University, overseeing a GYN Oncology clinic.

Dr. Dupont received his undergraduate degree in philosophy from Vassar College and an M.A. in philosophy from New York University. He studied pre-medical science at Columbia University and received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University. He also served as Assistant Chief Resident at MSK and completed his Medical Oncology Fellowship at MSK Cancer Center, his Internal Medicine Residency at the New-York Presbyterian Hospital—Cornell Campus, and his Internal Medicine Internship at The University of Michigan Medical Center in Ann Arbor.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. More information can be found at

View source version on

Editor Details

Last Updated: 17-Dec-2018